116 related articles for article (PubMed ID: 12204060)
1. ras Gene mutations and expression of Ras signal transduction mediators in gastric adenocarcinomas.
Yoo J; Park SY; Robinson RA; Kang SJ; Ahn WS; Kang CS
Arch Pathol Lab Med; 2002 Sep; 126(9):1096-100. PubMed ID: 12204060
[TBL] [Abstract][Full Text] [Related]
2. P21 protein expression and ras-oncogene mutations in gastric carcinoma: correlation with clinical data.
Kasper HU; Schneider-Stock R; Mellin W; Roessner A
Int J Oncol; 1998 Jan; 12(1):69-74. PubMed ID: 9454888
[TBL] [Abstract][Full Text] [Related]
3. Ki-ras and the characteristics of mouse lung tumors.
Ramakrishna G; Bialkowska A; Perella C; Birely L; Fornwald LW; Diwan BA; Shiao YH; Anderson LM
Mol Carcinog; 2000 Jul; 28(3):156-67. PubMed ID: 10942532
[TBL] [Abstract][Full Text] [Related]
4. Mutation of ras oncogene in gastric adenocarcinoma: association with histological phenotype.
Kim TY; Bang YJ; Kim WS; Kang SH; Lee KU; Choe KJ; Kim NK
Anticancer Res; 1997; 17(2B):1335-9. PubMed ID: 9137494
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type.
Ranzani GN; Luinetti O; Padovan LS; Calistri D; Renault B; Burrel M; Amadori D; Fiocca R; Solcia E
Cancer Epidemiol Biomarkers Prev; 1995; 4(3):223-31. PubMed ID: 7606196
[TBL] [Abstract][Full Text] [Related]
6. Infrequent point mutations of ras oncogenes in gastric cancers.
Nanus DM; Kelsen DP; Mentle IR; Altorki N; Albino AP
Gastroenterology; 1990 Apr; 98(4):955-60. PubMed ID: 2179035
[TBL] [Abstract][Full Text] [Related]
7. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.
Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698
[TBL] [Abstract][Full Text] [Related]
8. No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations.
Kimura K; Nagasaka T; Hoshizima N; Sasamoto H; Notohara K; Takeda M; Kominami K; Iishii T; Tanaka N; Matsubara N
J Int Med Res; 2007; 35(4):450-7. PubMed ID: 17697521
[TBL] [Abstract][Full Text] [Related]
9. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas.
Kumamoto H; Takahashi N; Ooya K
J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides.
Ross PJ; George M; Cunningham D; DiStefano F; Andreyev HJ; Workman P; Clarke PA
Mol Cancer Ther; 2001 Nov; 1(1):29-41. PubMed ID: 12467236
[TBL] [Abstract][Full Text] [Related]
11. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy.
Hongyo T; Buzard GS; Palli D; Weghorst CM; Amorosi A; Galli M; Caporaso NE; Fraumeni JF; Rice JM
Cancer Res; 1995 Jun; 55(12):2665-72. PubMed ID: 7780983
[TBL] [Abstract][Full Text] [Related]
12. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.
Sommerer F; Vieth M; Markwarth A; Röhrich K; Vomschloss S; May A; Ell C; Stolte M; Hengge UR; Wittekind C; Tannapfel A
Oncogene; 2004 Jan; 23(2):554-8. PubMed ID: 14724583
[TBL] [Abstract][Full Text] [Related]
13. Frequent overexpression, but not activation by point mutation, of ras genes in primary human gastric cancers.
Fujita K; Ohuchi N; Yao T; Okumura M; Fukushima Y; Kanakura Y; Kitamura Y; Fujita J
Gastroenterology; 1987 Dec; 93(6):1339-45. PubMed ID: 3315826
[TBL] [Abstract][Full Text] [Related]
14. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
15. The progression in the mouse skin carcinogenesis model correlates with ERK1/2 signaling.
Katsanakis KD; Gorgoulis V; Papavassiliou AG; Zoumpourlis VK
Mol Med; 2002 Oct; 8(10):624-37. PubMed ID: 12477973
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis.
Gotoh J; Obata M; Yoshie M; Kasai S; Ogawa K
Carcinogenesis; 2003 Mar; 24(3):435-42. PubMed ID: 12663502
[TBL] [Abstract][Full Text] [Related]
17. Activation of c-K-ras mutations in human gastrointestinal tumors.
Arber N; Shapira I; Ratan J; Stern B; Hibshoosh H; Moshkowitz M; Gammon M; Fabian I; Halpern Z
Gastroenterology; 2000 Jun; 118(6):1045-50. PubMed ID: 10833479
[TBL] [Abstract][Full Text] [Related]
18. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
[TBL] [Abstract][Full Text] [Related]
19. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.
Li S; Rosell R; Urban A; Font A; Ariza A; Armengol P; Abad A; Navas JJ; Monzo M
Lung Cancer; 1994 Jul; 11(1-2):19-27. PubMed ID: 8081702
[TBL] [Abstract][Full Text] [Related]
20. Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation.
Iida M; Towatari M; Nakao A; Iida H; Kiyoi H; Nakano Y; Tanimoto M; Saito H; Naoe T
Leukemia; 1999 Apr; 13(4):585-9. PubMed ID: 10214865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
